<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00621257</url>
  </required_header>
  <id_info>
    <org_study_id>1K23DK076979-01A1</org_study_id>
    <secondary_id>1K23DK076979-01A1</secondary_id>
    <nct_id>NCT00621257</nct_id>
  </id_info>
  <brief_title>Vitamin D Levels in Children With IBD</brief_title>
  <official_title>Optimization of Vitamin D Stores and Its Impact on the Bone Health and Disease Outcomes of Children and Adolescents With IBD.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children’s Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Crohn's and Colitis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NASPGHAN Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Children’s Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research has shown that children with Inflammatory Bowel Disease may have lower levels of
      vitamin D than healthy children, especially in the winter. Vitamin D is important for growing
      and maintaining healthy bones throughout life, and this is particularly important, since
      children with IBD frequently have low bone density. It may also be helpful in the treatment
      of IBD itself, because it helps reduce inflammation. Vitamin D levels are measured by the
      amount of 25 OHD in the blood; however, measuring this level on a regular basis is not yet
      the standard for children with IBD. The purpose of this study is to find the best way to
      treat low vitamin D levels, and to maintain good vitamin D levels throughout the year. It
      will also test whether having higher vitamin D levels will improve the bone health of
      children with IBD, and whether it will help them have milder disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vitamin D is essential for bone mineralization. The prevalence of vitamin D insufficiency
      [serum 25-hydroxy-vitamin D concentration (25OHD) ≤ 20 ng/mL] is high among adults with
      inflammatory bowel disease (IBD), and even higher in pediatric patients with IBD.
      Protein-losing enteropathy could represent both an etiologic factor for hypovitaminosis D,
      and an obstacle in treating it in IBD patients. There are currently no guidelines for the
      treatment of hypovitaminosis D in adults or children with IBD. Moreover we have obtained
      evidence that optimal vitamin D stores (25OHD ≥32 ng/mL) may not be maintained throughout the
      year in patients with IBD following current RDA recommendations. On the other hand, the
      prevalence of low bone mineral density is high among young patients with IBD, during a period
      in their lives when they should experience the most rapid acquisition of bone mass.
      Optimization of vitamin D status and its impact on the bone health of children with IBD has
      not been studied. In addition, vitamin D may play an important role in the regulation of the
      immune system as supported by animal models of colitis and in vitro human studies.

      Prospective studies of the effect of vitamin D supplementation on disease outcomes have not
      been undertaken in children with IBD to date. We aim to perform a) a randomized controlled
      trial to compare the efficacy of 3 regimens in treating vitamin D insufficiency in pediatric
      patients with IBD over a period of 6 weeks. We will also evaluate the effects of each regimen
      on markers of bone resorption, bone formation and parathyroid hormone levels, and the
      relationship between the magnitude of gastrointestinal protein loss, as reflected by
      clearance of fecal alpha -1-antitrypsin, and the efficacy of the treatment. b) We also aim to
      perform a randomized controlled trial to compare the efficacy of 2 regimens of different
      doses of oral vitamin D2 in maintaining optimal vitamin D stores in pediatric patients with
      IBD over a period of 2 years. We intend to study the effect of each regimen on a) bone mass
      acquisition (measured via DXA and pQCT) and bone strength (measured via pQCT), b) bone
      formation and resorption markers and parathyroid hormone, and c) disease outcomes and disease
      severity over the same period of time.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Maintenance phase outcome unattenable
  </why_stopped>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment of Low 25 Hydroxy Vitamin D Levels in Pediatric Patients With Inflammatory Bowel Disease</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in serum 25OHD levels after treatment with vitamin D formulations for 6 weeks in pediatric patients with inflammatory bowel disease.
25OHD is the most abundant vitamin D metabolite, which is bound to vitamin D binding protein. The measurement of its concentration in serum, reflects vitamin D stores.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maintenance of 25 Hydroxy Vitamin D Levels in Pediatric Patients With Inflammatory Bowel Disease</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of pediatric patients with inflammatory bowel disease who maintained their serum 25OHD level at or above 32 ng/mL at all study visits over the duration of the maintenance study 25OHD is the most abundant vitamin D metabolite, which is bound to vitamin D binding protein. The measurement of its concentration in serum, reflects vitamin D stores. Concentration at or above 32 ng/mL has been identified as optimal vitamin D level for bone health by majority of experts.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Inflammatory Bowel Disease</condition>
  <condition>Crohn's Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2,000 IU/day of ergocalciferol orally for 6 weeks (control arm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2,000 IU/day of cholecalciferol orally for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50,000 IU of ergocalciferol once a week orally for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400 IU/day of ergocalciferol orally over 2 years (control arm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2,000 IU/day of ergocalciferol orally from November 1 to April 30, and 1,000 IU/day of ergocalciferol orally for the remainder of the year over 2 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ergocalciferol</intervention_name>
    <description>8000 units/ml</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Maintenance A</arm_group_label>
    <arm_group_label>Maintenance B</arm_group_label>
    <other_name>Vitamin D2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>400 units per drop</description>
    <arm_group_label>Treatment B</arm_group_label>
    <other_name>Vitamin D3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of inflammatory bowel disease

          -  serum 25OHD level ≤ 20 ng/mL (Treatment Trial)

          -  serum 25OHD level &gt; 20 ng/mL (Maintenance Trial)

        Exclusion Criteria:

          -  Patients unable to take medications by mouth, pregnant, with liver/kidney failure,
             receiving anticonvulsant medications (specifically, phenobarbital, carbamazepine and
             phenytoin, since they lead to increased vitamin D metabolism through hepatic induction
             of the cytochrome P450 (CYP450) hydroxylase enzymes), regularly attending a tanning
             salon (once weekly or more), currently being treated for hypovitaminosis D with
             therapeutic doses of vitamin D (&gt; 800 IU per day) and unwilling to discontinue this
             regimen.

          -  patients on growth hormone, anabolic steroid hormones, calcitonin, bisphosphonates
             (Maintenance Trial only)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen Pappa, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children’s Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital, Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2008</study_first_submitted>
  <study_first_submitted_qc>February 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2008</study_first_posted>
  <results_first_submitted>December 27, 2016</results_first_submitted>
  <results_first_submitted_qc>December 27, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 17, 2017</results_first_posted>
  <last_update_submitted>February 18, 2017</last_update_submitted>
  <last_update_submitted_qc>February 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children’s Hospital</investigator_affiliation>
    <investigator_full_name>Helen Pappa</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>IBD</keyword>
  <keyword>Inflammatory Bowel Disease</keyword>
  <keyword>Crohn's Disease</keyword>
  <keyword>Ulcerative Colitis</keyword>
  <keyword>Vitamin D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment A</title>
          <description>2,000 IU/day of vitamin D2 orally for 6 weeks (control arm)
ergocalciferol: 8000 units/ml</description>
        </group>
        <group group_id="P2">
          <title>Treatment B</title>
          <description>2,000 IU/day of vitamin D3 orally for 6 weeks
Cholecalciferol: 400 units per drop</description>
        </group>
        <group group_id="P3">
          <title>Treatment C</title>
          <description>50,000 IU of vitamin D2 once a week orally for 6 weeks
ergocalciferol: 8000 units/ml</description>
        </group>
        <group group_id="P4">
          <title>Maintenance A</title>
          <description>400 IU/day of vitamin D2 orally over 2 years (control arm)
ergocalciferol: 8000 units/ml</description>
        </group>
        <group group_id="P5">
          <title>Maintenance B</title>
          <description>2,000 IU/day of vitamin D2 orally from November 1 to April 30, and 1,000 IU/day of vitamin D2 orally for the remainder of the year over 2 years
ergocalciferol: 8000 units/ml</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="32"/>
                <participants group_id="P5" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment A</title>
          <description>2,000 IU/day of vitamin D2 orally for 6 weeks (control arm)
ergocalciferol: 8000 units/ml</description>
        </group>
        <group group_id="B2">
          <title>Treatment B</title>
          <description>2,000 IU/day of vitamin D3 orally for 6 weeks
Cholecalciferol: 400 units per drop</description>
        </group>
        <group group_id="B3">
          <title>Treatment C</title>
          <description>50,000 IU of vitamin D2 once a week orally for 6 weeks
ergocalciferol: 8000 units/ml</description>
        </group>
        <group group_id="B4">
          <title>Maintenance A</title>
          <description>400 IU/day of vitamin D2 orally over 2 years (control arm)
ergocalciferol: 8000 units/ml</description>
        </group>
        <group group_id="B5">
          <title>Maintenance B</title>
          <description>2,000 IU/day of vitamin D2 orally from November 1 to April 30, and 1,000 IU/day of vitamin D2 orally for the remainder of the year over 2 years
ergocalciferol: 8000 units/ml</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="23"/>
            <count group_id="B4" value="32"/>
            <count group_id="B5" value="31"/>
            <count group_id="B6" value="134"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.9" spread="3"/>
                    <measurement group_id="B2" value="14.7" spread="3.5"/>
                    <measurement group_id="B3" value="16.3" spread="3.2"/>
                    <measurement group_id="B4" value="15.1" spread="3.1"/>
                    <measurement group_id="B5" value="14.5" spread="3.1"/>
                    <measurement group_id="B6" value="15.2" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment of Low 25 Hydroxy Vitamin D Levels in Pediatric Patients With Inflammatory Bowel Disease</title>
        <description>Change in serum 25OHD levels after treatment with vitamin D formulations for 6 weeks in pediatric patients with inflammatory bowel disease.
25OHD is the most abundant vitamin D metabolite, which is bound to vitamin D binding protein. The measurement of its concentration in serum, reflects vitamin D stores.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>2,000 IU/day of vitamin D2 orally for 6 weeks (control arm)
ergocalciferol: 8000 units/ml</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>2,000 IU/day of vitamin D3 orally for 6 weeks
Cholecalciferol: 400 units per drop</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>50,000 IU of vitamin D2 once a week orally for 6 weeks
ergocalciferol: 8000 units/ml</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment of Low 25 Hydroxy Vitamin D Levels in Pediatric Patients With Inflammatory Bowel Disease</title>
          <description>Change in serum 25OHD levels after treatment with vitamin D formulations for 6 weeks in pediatric patients with inflammatory bowel disease.
25OHD is the most abundant vitamin D metabolite, which is bound to vitamin D binding protein. The measurement of its concentration in serum, reflects vitamin D stores.</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="1.8"/>
                    <measurement group_id="O2" value="16.4" spread="2.0"/>
                    <measurement group_id="O3" value="25.4" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance of 25 Hydroxy Vitamin D Levels in Pediatric Patients With Inflammatory Bowel Disease</title>
        <description>Percentage of pediatric patients with inflammatory bowel disease who maintained their serum 25OHD level at or above 32 ng/mL at all study visits over the duration of the maintenance study 25OHD is the most abundant vitamin D metabolite, which is bound to vitamin D binding protein. The measurement of its concentration in serum, reflects vitamin D stores. Concentration at or above 32 ng/mL has been identified as optimal vitamin D level for bone health by majority of experts.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Maintenance A</title>
            <description>400 IU/day of vitamin D2 orally over 2 years (control arm)
ergocalciferol: 8000 units/ml</description>
          </group>
          <group group_id="O2">
            <title>Maintenance B</title>
            <description>2,000 IU/day of vitamin D2 orally from November 1 to April 30, and 1,000 IU/day of vitamin D2 orally for the remainder of the year over 2 years
ergocalciferol: 8000 units/ml</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance of 25 Hydroxy Vitamin D Levels in Pediatric Patients With Inflammatory Bowel Disease</title>
          <description>Percentage of pediatric patients with inflammatory bowel disease who maintained their serum 25OHD level at or above 32 ng/mL at all study visits over the duration of the maintenance study 25OHD is the most abundant vitamin D metabolite, which is bound to vitamin D binding protein. The measurement of its concentration in serum, reflects vitamin D stores. Concentration at or above 32 ng/mL has been identified as optimal vitamin D level for bone health by majority of experts.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks while participant was on study medication for treatment trial</time_frame>
      <desc>For 1 year, while participant was on study medication for the maintenance trial.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment A</title>
          <description>2,000 IU/day of vitamin D2 orally for 6 weeks (control arm)
ergocalciferol: 8000 units/ml</description>
        </group>
        <group group_id="E2">
          <title>Treatment B</title>
          <description>2,000 IU/day of vitamin D3 orally for 6 weeks
Cholecalciferol: 400 units per drop</description>
        </group>
        <group group_id="E3">
          <title>Treatment C</title>
          <description>50,000 IU of vitamin D2 once a week orally for 6 weeks
ergocalciferol: 8000 units/ml</description>
        </group>
        <group group_id="E4">
          <title>Maintenance A</title>
          <description>400 IU per day of oral vitamin D2
ergocalciferol 8000 IU/ml</description>
        </group>
        <group group_id="E5">
          <title>Maintenance B</title>
          <description>1,000 IU of oral vitamin D2 per day from May to October and 2,000 IU of oral vitamin D2 per day of oral vitamin D2 per day from November to April
ergocalciferol 8000 IU/ml</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>irregular heart beat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>sensitive eyes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Metallic taste</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Unusual tiredness, or weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Muscle pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Increased thirst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased urination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>itching skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rash on face and body</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Calcium deposit in tissues outside of bones</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Helen Pappa, MD, MPH, Principal Investigator</name_or_title>
      <organization>children's Hospital Boston</organization>
      <phone>617-355-6058</phone>
      <email>helen.pappa@childrens.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

